8-K Announcements
6May 6, 2026·SEC
Apr 23, 2026·SEC
Mar 30, 2026·SEC
Sight Sciences, Inc. (SGHT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Sight Sciences, Inc. (SGHT) stock price & volume — 10-year historical chart
Sight Sciences, Inc. (SGHT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Sight Sciences, Inc. (SGHT) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 4, 2026 | $0.08vs $0.15+46.7% | $20Mvs $20M+0.2% |
| Q4 2025 | Nov 6, 2025 | $0.16vs $0.26+38.5% | $20Mvs $20M-2.2% |
| Q3 2025 | Aug 7, 2025 | $0.23vs $0.25+8.0% | $20Mvs $18M+10.3% |
| Q2 2025 | May 8, 2025 | $0.28vs $0.29+3.4% | $18Mvs $18M-5.3% |
Sight Sciences, Inc. (SGHT) competitors in Vision, dental, and ENT devices — business model, growth, and fundamentals comparison
Sight Sciences, Inc. (SGHT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Sight Sciences, Inc. (SGHT) annual income statement — 10-year revenue, gross profit & net income history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 7.53M | 23.35M | 27.64M | 48.96M | 71.33M | 81.06M | 79.87M | 77.36M | 79.55M |
| Revenue Growth % | - | 210.07% | 18.38% | 77.12% | 45.7% | 13.63% | -1.47% | -3.13% | 1.85% |
| Cost of Goods Sold | 2.34M | 6.54M | 9.21M | 8.61M | 12.36M | 11.88M | 11.58M | 10.7M | 11M |
| COGS % of Revenue | 31.05% | 28.03% | 33.32% | 17.59% | 17.33% | 14.66% | 14.5% | 13.83% | - |
| Gross Profit | 5.19M▲ 0% | 16.8M▲ 223.7% | 18.43M▲ 9.7% | 40.35M▲ 118.9% | 58.97M▲ 46.2% | 69.17M▲ 17.3% | 68.28M▼ 1.3% | 66.67M▼ 2.4% | 68.55M▲ 0% |
| Gross Margin % | 68.95% | 71.97% | 66.68% | 82.41% | 82.67% | 85.34% | 85.5% | 86.17% | 86.17% |
| Gross Profit Growth % | - | 223.65% | 9.68% | 118.9% | 46.16% | 17.31% | -1.29% | -2.37% | - |
| Operating Expenses | 19.49M | 40.84M | 50.62M | 91.82M | 142.92M | 126.45M | 118.82M | 103.77M | 104.2M |
| OpEx % of Revenue | 258.82% | 174.93% | 183.14% | 187.56% | 200.37% | 156% | 148.77% | 134.13% | - |
| Selling, General & Admin | 14.06M | 32.72M | 41.74M | 76.19M | 120.06M | 108.89M | 100.83M | 89.16M | 91.48M |
| SG&A % of Revenue | 186.76% | 140.14% | 151.03% | 155.63% | 168.32% | 134.34% | 126.24% | 115.25% | - |
| Research & Development | 5.43M | 8.12M | 8.87M | 15.63M | 22.86M | 17.56M | 17.99M | 14.61M | 12.72M |
| R&D % of Revenue | 72.06% | 34.8% | 32.11% | 31.93% | 32.05% | 21.66% | 22.53% | 18.88% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -14.3M▲ 0% | -24.04M▼ 68.1% | -32.19M▼ 33.9% | -51.48M▼ 59.9% | -83.95M▼ 63.1% | -57.27M▲ 31.8% | -50.53M▲ 11.8% | -37.1M▲ 26.6% | -35.65M▲ 0% |
| Operating Margin % | -189.87% | -102.96% | -116.45% | -105.15% | -117.7% | -70.66% | -63.27% | -47.95% | -44.82% |
| Operating Income Growth % | - | -68.14% | -33.9% | -59.93% | -63.09% | 31.78% | 11.77% | 26.58% | - |
| EBITDA | -14.23M | -23.61M | -31.63M | -50.28M | -82.7M | -56.66M | -49.82M | -36.61M | -35.32M |
| EBITDA Margin % | -189.03% | -101.11% | -114.45% | -102.7% | -115.94% | -69.9% | -62.38% | -47.32% | -44.39% |
| EBITDA Growth % | - | -65.85% | -34% | -58.93% | -64.49% | 31.49% | 12.07% | 26.51% | 28.05% |
| D&A (Non-Cash Add-back) | 63K | 432K | 554K | 1.2M | 1.25M | 614K | 712K | 487K | 338K |
| EBIT | -14.3M | -23.9M | -32.23M | -58.41M | -81.73M | -50.03M | -46.61M | -37.1M | -24.25M |
| Net Interest Income | 1K | -1.79M | -2.37M | -4.37M | -4.47M | -5.41M | -4.66M | -1.17M | -2.02M |
| Interest Income | 1K | 174K | 30K | 0 | 0 | 0 | 0 | 3.97M | 1.86M |
| Interest Expense | 0 | 1.96M | 2.4M | 4.37M | 4.47M | 5.41M | 4.66M | 5.14M | 2.61M |
| Other Income/Expense | 1K | -1.82M | -2.44M | -11.29M | -2.24M | 1.84M | -739K | -1.32M | -1.62M |
| Pretax Income | -14.3M▲ 0% | -25.86M▼ 80.9% | -34.63M▼ 33.9% | -62.77M▼ 81.3% | -86.19M▼ 37.3% | -55.44M▲ 35.7% | -51.27M▲ 7.5% | -38.42M▲ 25.1% | -37.27M▲ 0% |
| Pretax Margin % | -189.85% | -110.76% | -125.3% | -128.22% | -120.84% | -68.39% | -64.2% | -49.66% | -46.85% |
| Income Tax | -6K | 8K | 61K | 188K | 47K | 110K | 236K | 10K | -20K |
| Effective Tax Rate % | 0.04% | -0.03% | -0.18% | -0.3% | -0.05% | -0.2% | -0.46% | -0.03% | 0.05% |
| Net Income | -14.29M▲ 0% | -25.87M▼ 81.0% | -34.69M▼ 34.1% | -62.96M▼ 81.5% | -86.24M▼ 37.0% | -55.55M▲ 35.6% | -51.51M▲ 7.3% | -38.43M▲ 25.4% | -37.25M▲ 0% |
| Net Margin % | -189.77% | -110.8% | -125.52% | -128.61% | -120.9% | -68.53% | -64.49% | -49.67% | -46.83% |
| Net Income Growth % | - | -81.03% | -34.11% | -81.48% | -36.98% | 35.59% | 7.27% | 25.4% | 24.58% |
| Net Income (Continuing) | -14.29M | -25.87M | -34.69M | -62.96M | -86.24M | -55.55M | -51.51M | -38.43M | -37.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.44▲ 0% | -0.77▼ 75.0% | -0.74▲ 3.9% | -1.33▼ 79.7% | -1.80▼ 35.3% | -1.14▲ 36.7% | -1.03▲ 9.6% | -0.74▲ 28.2% | -0.69▲ 0% |
| EPS Growth % | - | -75% | 3.9% | -79.73% | -35.34% | 36.67% | 9.65% | 28.16% | 27.71% |
| EPS (Basic) | -0.44 | -0.55 | -0.74 | -1.33 | -1.80 | -1.14 | -1.03 | -0.74 | - |
| Diluted Shares Outstanding | 32.2M | 33.63M | 46.77M | 47.5M | 47.85M | 48.63M | 50.13M | 52.15M | 53.94M |
| Basic Shares Outstanding | 32.2M | 33.63M | 46.77M | 47.5M | 47.85M | 48.63M | 50.13M | 52.15M | 53.94M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Sight Sciences, Inc. (SGHT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.16M | 28M | 70.63M | 277.04M | 209.68M | 162.87M | 139.77M | 112.73M | 106.51M |
| Cash & Short-Term Investments | 4.24M | 21.24M | 61.51M | 260.69M | 185M | 138.13M | 120.36M | 91.97M | 84.96M |
| Cash Only | 4.24M | 21.24M | 61.51M | 260.69M | 185M | 138.13M | 120.36M | 91.97M | 84.96M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.81M | 4.09M | 5.36M | 8.71M | 15.15M | 14.29M | 10.79M | 9.74M | 10.6M |
| Days Sales Outstanding | 87.98 | 64 | 70.82 | 64.93 | 77.51 | 64.34 | 49.29 | 45.98 | 45.53 |
| Inventory | 486K | 2.24M | 2.6M | 3.48M | 6.11M | 7.85M | 6.33M | 7.77M | 7.01M |
| Days Inventory Outstanding | 75.87 | 125.16 | 102.97 | 147.31 | 180.54 | 241.13 | 199.35 | 265.02 | 240.27 |
| Other Current Assets | 0 | 0 | 0 | 0 | 3.42M | 2.6M | 2.31M | 3.26M | 3.95M |
| Total Non-Current Assets | 930K | 2.74M | 2.17M | 3.15M | 3.4M | 3.78M | 3.06M | 2.57M | 3.19M |
| Property, Plant & Equipment | 868K | 2.57M | 1.79M | 2.95M | 3.19M | 3.1M | 2.52M | 2.05M | 2.82M |
| Fixed Asset Turnover | 8.68x | 9.08x | 15.47x | 16.60x | 22.40x | 26.16x | 31.76x | 37.77x | 34.83x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 62K | 168K | 386K | 202K | 211K | 682K | 550K | 518K | 1.82M |
| Total Assets | 8.09M▲ 0% | 30.74M▲ 279.8% | 72.81M▲ 136.8% | 280.19M▲ 284.8% | 213.07M▼ 24.0% | 166.65M▼ 21.8% | 142.84M▼ 14.3% | 115.3M▼ 19.3% | 109.7M▲ 0% |
| Asset Turnover | 0.93x | 0.76x | 0.38x | 0.17x | 0.33x | 0.49x | 0.56x | 0.67x | 0.69x |
| Asset Growth % | - | 279.8% | 136.84% | 284.84% | -23.95% | -21.79% | -14.29% | -19.28% | -72.26% |
| Total Current Liabilities | 2.9M | 7.34M | 9.31M | 13.5M | 17.82M | 12.25M | 15.47M | 11.03M | 18.16M |
| Accounts Payable | 1.88M | 2.31M | 2.16M | 3.35M | 2.69M | 1.73M | 1.69M | 1.34M | 1.49M |
| Days Payables Outstanding | 293.34 | 129.12 | 85.53 | 142.06 | 79.37 | 53.18 | 53.3 | 45.83 | 55.12 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 2.22M | 0 | 0 | 3.8M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 328K | 0 | 4.07M | 5.99M | 7.35M | 4.53M | 9.68M | 9.21M | 14.37M |
| Current Ratio | 2.47x | 3.82x | 7.58x | 20.52x | 11.77x | 13.29x | 9.04x | 10.22x | 10.22x |
| Quick Ratio | 2.31x | 3.51x | 7.30x | 20.26x | 11.43x | 12.65x | 8.63x | 9.52x | 9.52x |
| Cash Conversion Cycle | -129.49 | 60.04 | 88.26 | 70.19 | 178.68 | 252.3 | 195.34 | 265.18 | 230.68 |
| Total Non-Current Liabilities | 34.16M | 78.09M | 152.34M | 34.58M | 35.18M | 34.18M | 39.85M | 40.33M | 37.64M |
| Long-Term Debt | 34.15M | 12.86M | 31.95M | 32.66M | 33.31M | 31.71M | 39.36M | 40.3M | 0 |
| Capital Lease Obligations | 0 | 528K | 134K | 1.04M | 635K | 914K | 473K | 0 | 230K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 7K | 64.7M | 120.25M | 879K | 1.23M | 1.56M | 19K | 31K | 37.7M |
| Total Liabilities | 37.06M | 85.42M | 161.66M | 48.08M | 53M | 46.44M | 55.32M | 51.36M | 55.8M |
| Total Debt | 34.15M | 13.94M | 32.48M | 34.21M | 34.98M | 35.41M | 40.36M | 40.77M | 3.8M |
| Net Debt | 29.91M | -7.3M | -29.03M | -226.48M | -150.02M | -102.72M | -80M | -51.19M | -81.17M |
| Debt / Equity | - | - | - | 0.15x | 0.22x | 0.29x | 0.46x | 0.64x | 0.64x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -0.11x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 2.30x |
| Interest Coverage | - | -12.19x | -13.41x | -13.38x | -18.30x | -9.25x | -10.00x | -7.21x | -9.29x |
| Total Equity | -28.96M▲ 0% | -54.68M▼ 88.8% | -88.85M▼ 62.5% | 232.11M▲ 361.2% | 160.08M▼ 31.0% | 120.22M▼ 24.9% | 87.52M▼ 27.2% | 63.94M▼ 26.9% | 53.9M▲ 0% |
| Equity Growth % | - | -88.81% | -62.48% | 361.24% | -31.03% | -24.9% | -27.19% | -26.94% | -120.92% |
| Book Value per Share | -0.90 | -1.63 | -1.90 | 4.89 | 3.35 | 2.47 | 1.75 | 1.23 | 1.00 |
| Total Shareholders' Equity | -28.96M | -54.68M | -88.85M | 232.11M | 160.08M | 120.22M | 87.52M | 63.94M | 53.9M |
| Common Stock | 9K | 9K | 9K | 48K | 48K | 49K | 51K | 54K | 54K |
| Retained Earnings | -29.48M | -55.35M | -90.04M | -153M | -239.24M | -294.79M | -346.3M | -384.72M | -397.7M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -34.15M | -64.49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sight Sciences, Inc. (SGHT) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -14.47M | -25M | -32.17M | -52.54M | -75.97M | -47.18M | -22.35M | -29.69M | -29.69M |
| Operating CF Margin % | -192.23% | -107.06% | -116.4% | -107.32% | -106.5% | -58.21% | -27.99% | -38.38% | - |
| Operating CF Growth % | - | -72.69% | -28.71% | -63.3% | -44.59% | 37.89% | 52.63% | -32.85% | -1444.27% |
| Net Income | -14.29M | -25.87M | -34.69M | -62.96M | -86.24M | -55.55M | -51.51M | -38.43M | -37.25M |
| Depreciation & Amortization | 63K | 295K | 554K | 632K | 710K | 614K | 712K | 487K | 690K |
| Stock-Based Compensation | 52K | 118K | 497K | 5.08M | 12.96M | 14.58M | 17.08M | 13.05M | 11.66M |
| Deferred Taxes | 0 | 0 | 0 | 7.76M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 58K | 800K | 684K | 1.27M | 2.3M | 2.3M | 2.37M | 1.59M | 3.63M |
| Working Capital Changes | -358K | -341K | 784K | -4.33M | -5.7M | -9.13M | 9M | -6.39M | -3.86M |
| Change in Receivables | -1.42M | -2.32M | -1.48M | -3.69M | -6.84M | 661K | 3.54M | 912K | -1.14M |
| Change in Inventory | -184K | -1.8M | -1.72M | -1.31M | -3.25M | -2.16M | 1.63M | -1.44M | -1.2M |
| Change in Payables | 1M | 168K | 448K | 1.17M | -694K | -883K | 336K | -348K | -943K |
| Cash from Investing | -570K | -672K | -953K | -813K | -970K | -791K | -385K | -224K | -284K |
| Capital Expenditures | -570K | -672K | -953K | -813K | -970K | -791K | -385K | -224K | -284K |
| CapEx % of Revenue | 7.57% | 2.88% | 3.45% | 1.66% | 1.36% | 0.98% | 0.48% | 0.29% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 12.2M | 42.66M | 73.4M | 252.53M | 1.25M | 1.1M | 4.96M | 1.79M | 1.86M |
| Debt Issued (Net) | 0 | 14M | 20.48M | 0 | 0 | 0 | 4.15M | 0 | 0 |
| Equity Issued (Net) | 12.23M | 30.75M | 53.08M | 256.68M | 1.25M | 1.33M | 1.07M | 1.85M | 1.76M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1K |
| Other Financing | -23K | -2.09M | -154K | -4.15M | 0 | -224K | -261K | -58K | 104K |
| Net Change in Cash | -2.84M▲ 0% | 17M▲ 698.0% | 40.27M▲ 137.0% | 199.18M▲ 394.6% | -75.69M▼ 138.0% | -46.87M▲ 38.1% | -17.77M▲ 62.1% | -28.13M▼ 58.3% | -23.54M▲ 0% |
| Free Cash Flow | -15.04M▲ 0% | -25.67M▼ 70.6% | -33.13M▼ 29.1% | -53.35M▼ 61.1% | -76.94M▼ 44.2% | -47.98M▲ 37.6% | -22.74M▲ 52.6% | -29.92M▼ 31.6% | -25.4M▲ 0% |
| FCF Margin % | -199.8% | -109.94% | -119.85% | -108.98% | -107.86% | -59.19% | -28.47% | -38.67% | -31.93% |
| FCF Growth % | - | -70.61% | -29.05% | -61.06% | -44.2% | 37.64% | 52.61% | -31.59% | -3.94% |
| FCF per Share | -0.47 | -0.76 | -0.71 | -1.12 | -1.61 | -0.99 | -0.45 | -0.57 | -0.57 |
| FCF Conversion (FCF/Net Income) | 1.01x | 0.97x | 0.93x | 0.83x | 0.88x | 0.85x | 0.43x | 0.77x | 0.68x |
| Interest Paid | 0 | 1.15M | 1.29M | 0 | 0 | 0 | 0 | 0 | 1.06M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sight Sciences, Inc. (SGHT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -87.9% | -43.98% | -39.64% | -49.59% | -50.74% | -59.1% |
| Return on Invested Capital (ROIC) | - | - | -686.25% | -802.98% | -311.76% | -302.85% | -274.4% | -274.4% |
| Gross Margin | 71.97% | 66.68% | 82.41% | 82.67% | 85.34% | 85.5% | 86.17% | 86.17% |
| Net Margin | -110.8% | -125.52% | -128.61% | -120.9% | -68.53% | -64.49% | -49.67% | -46.83% |
| Debt / Equity | - | - | 0.15x | 0.22x | 0.29x | 0.46x | 0.64x | 0.64x |
| Interest Coverage | -12.19x | -13.41x | -13.38x | -18.30x | -9.25x | -10.00x | -7.21x | -9.29x |
| FCF Conversion | 0.97x | 0.93x | 0.83x | 0.88x | 0.85x | 0.43x | 0.77x | 0.68x |
| Revenue Growth | 210.07% | 18.38% | 77.12% | 45.7% | 13.63% | -1.47% | -3.13% | 1.85% |
Sight Sciences, Inc. (SGHT) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
Apr 23, 2026·SEC
Mar 30, 2026·SEC
Sight Sciences, Inc. (SGHT) stock FAQ — growth, dividends, profitability & financials explained
Sight Sciences, Inc. (SGHT) reported $79.6M in revenue for fiscal year 2025. This represents a 956% increase from $7.5M in 2018.
Sight Sciences, Inc. (SGHT) saw revenue decline by 3.1% over the past year.
Sight Sciences, Inc. (SGHT) reported a net loss of $37.3M for fiscal year 2025.
Sight Sciences, Inc. (SGHT) has a return on equity (ROE) of -50.7%. Negative ROE indicates the company is unprofitable.
Sight Sciences, Inc. (SGHT) had negative free cash flow of $25.4M in fiscal year 2025, likely due to heavy capital investments.
Sight Sciences, Inc. (SGHT) financial analysis — history, returns, DCA and operating performance tools
Historical returns with dividends reinvested
Dollar cost averaging vs lump sum
Yield, growth, payout safety & DRIP
EPS trends, net income & profitability
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of market, efficiency and balance-sheet ratios
DCF intrinsic value, peer multiples & estimates